R
Recursion Pharmaceuticals, Inc.
RXRX · NASDAQ · Healthcare · 1.7B
Closing price
$4.36
+10.38% · last session
Graham & Buffett's criteria
published figures · last financial year
Price / earningsP/E
—
Price / net assetsP/B
1.7×
Enterprise value / EBITDAEV/EBITDA
-2.3×
Free cash flow yieldFCF yield
-19.4%
Return on equityROE
-57.0%
Operating margin
-867.9%
Net debt / EBITDAbalance-sheet strength
1.2×
Interest coverage
-358.1×
How we read it
an educational summary · not advice
Figures provided for information and education — they do not constitute personalized investment advice. Investing carries a risk of capital loss.